{"id":399945,"date":"2025-02-20T00:00:00","date_gmt":"2025-02-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/?post_type=report&#038;p=399945"},"modified":"2026-03-31T10:26:58","modified_gmt":"2026-03-31T10:26:58","slug":"unneim0017-2025-biopharma-rheumatoid-arthritis-unmet-need-unmet-need-tnfi-refractory-rheumatoid-arthritis-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0017-2025-biopharma-rheumatoid-arthritis-unmet-need-unmet-need-tnfi-refractory-rheumatoid-arthritis-us-eu\/","title":{"rendered":"Rheumatoid Arthritis &#8211; Unmet Need &#8211; Unmet Need &#8211; TNFi-Refractory Rheumatoid Arthritis (US\/EU)"},"content":{"rendered":"<p>Rheumatoid arthritis (<abbr title=\"rheumatoid arthritis\">RA<\/abbr>) patients who are refractory to one or more tumor necrosis factor (<abbr title=\"tumor necrosis factor\">TNF<\/abbr>)-alpha inhibitors are generally prescribed a non-<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-targeted therapy (e.g., Bristol Myers Squibb\u2019s Orencia, Roche\u2019s Actemra \/ RoActemra, Roche\u2019s Rituxan \/ MabThera, AbbVie\u2019s Rinvoq, Pfizer\u2019s Xeljanz, Eli Lilly \/ Incyte\u2019s Olumiant). Non-invasive targeted therapies such as <abbr title=\"Janus kinase\">JAK<\/abbr> inhibitors offer more treatment options, but safety data on <abbr title=\"Janus kinase\">JAK<\/abbr> inhibitors indicate a risk of serious infections, cardiovascular events, and\/or malignancy, restricting these agents\u2019 use in older patients with comorbidities. Although the <abbr title=\"rheumatoid arthritis\">RA<\/abbr> therapy market offers multiple efficacious and relatively safe agents, patients refractory to <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-alpha inhibitors have limited options; therefore, substantial unmet need remains in the treatment of <abbr title=\"tumor necrosis factor\">TNF<\/abbr> inhibitor-refractory <abbr title=\"rheumatoid arthritis\">RA<\/abbr>. .<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the treatment drivers and goals for <abbr title=\"tumor necrosis factor-alpha inhibitor\">TNFi<\/abbr>-refractory <abbr title=\"rheumatoid arthritis\">RA<\/abbr>?<\/li>\n<li>Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies perform on key clinical and nonclinical attributes for <abbr title=\"tumor necrosis factor-alpha inhibitor\">TNF<\/abbr> inhibitor-refractory <abbr title=\"rheumatoid arthritis\">RA<\/abbr>?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in <abbr title=\"tumor necrosis factor-alpha inhibitor\">TNF<\/abbr> inhibitor-refractory <abbr title=\"rheumatoid arthritis\">RA<\/abbr>?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to U.S. and European rheumatologists for a hypothetical new <abbr title=\"tumor necrosis factor-alpha inhibitor\">TNF<\/abbr> inhibitor-refractory <abbr title=\"rheumatoid arthritis\">RA<\/abbr> drug?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><a>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/a><\/p>\n<ul class=\"round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<li>Analyze market scenarios for different target product profiles using the <abbr title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 32 European rheumatologists fielded in December 2024<\/p>\n<p><strong>Key companies:<\/strong> Amgen, Roche,\u00a0Bristol Myers Squibb, Pfizer, ELi Lilly, AbbVie<\/p>\n<p><strong>Key drugs:<\/strong> Enbrel, Rituxan \/ MabThera, Orencia, Actemra \/ RoActemra, Xeljanz, Olumiant, Rinvoq<\/p>\n","protected":false},"template":"","class_list":["post-399945","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatoid-arthritis","biopharma-therapy-areas-rheumatology","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/399945","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/399945\/revisions"}],"predecessor-version":[{"id":399975,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/399945\/revisions\/399975"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=399945"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}